CA2303775A1 - Methods to improve immunogenicity of antigens and specificity of antibodies - Google Patents

Methods to improve immunogenicity of antigens and specificity of antibodies Download PDF

Info

Publication number
CA2303775A1
CA2303775A1 CA002303775A CA2303775A CA2303775A1 CA 2303775 A1 CA2303775 A1 CA 2303775A1 CA 002303775 A CA002303775 A CA 002303775A CA 2303775 A CA2303775 A CA 2303775A CA 2303775 A1 CA2303775 A1 CA 2303775A1
Authority
CA
Canada
Prior art keywords
peptide
hapten
antibody
conformation
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002303775A
Other languages
English (en)
French (fr)
Inventor
Judith Fitzpatrick
Regina Lenda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serex Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2303775A1 publication Critical patent/CA2303775A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002303775A 1997-09-19 1998-09-18 Methods to improve immunogenicity of antigens and specificity of antibodies Abandoned CA2303775A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5937897P 1997-09-19 1997-09-19
US9045898P 1998-06-24 1998-06-24
US60/059,378 1998-06-24
US60/090,458 1998-06-24
PCT/US1998/019660 WO1999013907A2 (en) 1997-09-19 1998-09-18 Methods to improve immunogenicity of antigens and specificity of antibodies

Publications (1)

Publication Number Publication Date
CA2303775A1 true CA2303775A1 (en) 1999-03-25

Family

ID=26738686

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303775A Abandoned CA2303775A1 (en) 1997-09-19 1998-09-18 Methods to improve immunogenicity of antigens and specificity of antibodies

Country Status (6)

Country Link
US (5) US6455047B1 (https=)
EP (1) EP1015028A2 (https=)
JP (1) JP2001516567A (https=)
AU (1) AU749305B2 (https=)
CA (1) CA2303775A1 (https=)
WO (1) WO1999013907A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6710190B1 (en) 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
PT1185524E (pt) * 1999-05-28 2005-04-29 Warner Lambert Co Analogos de gaba substituidos por 3-heteroarilalquilo
GB0031079D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Vaccine
FR2877668B1 (fr) * 2004-11-10 2007-07-06 Gemac Sa Procede de couplage de molecules non immunogenes, compose intermediaire, produit final obtenu et utilisations
WO2009120954A2 (en) * 2008-03-27 2009-10-01 The Scripps Research Institute Nicotine immunoconjugates
US8603828B2 (en) * 2009-11-18 2013-12-10 Bio-Rad Laboratories, Inc. Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms
US20160116489A1 (en) * 2014-10-23 2016-04-28 Biomedomics, Inc. Lateral flow immunoassay method of simultaneously detecting hemoglobin s, hemoglobin c, and hemoglobin a in newborns, infants, children, and adults
CN106053788A (zh) * 2016-07-21 2016-10-26 苏州博源医疗科技有限公司 一种可替宁均相酶免疫检测试剂及其制备和检测方法
US20190343951A1 (en) * 2017-01-13 2019-11-14 National Research Council Of Canada Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines
BR112019019630A2 (pt) 2017-05-19 2020-04-14 Philip Morris Products S.A. teste diagnóstico para distinguir o status de tabagismo de um sujeito
WO2019094909A1 (en) * 2017-11-13 2019-05-16 Matsfide, Inc. Vaccine development methodology based on an adhesion molecule
KR20210141990A (ko) * 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
CN110642743B (zh) * 2019-10-18 2021-01-01 中国农业大学 硝呋酚酰肼半抗原和人工抗原及其制备方法与应用
CN110724671A (zh) * 2019-10-31 2020-01-24 浙江蓝盾药业有限公司 杂交瘤细胞株1g8、抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647654A (en) 1984-10-29 1987-03-03 Molecular Diagnostics, Inc. Peptides useful in preparing hemoglobin A1c immunogens
CA1339952C (en) * 1984-10-29 1998-07-14 William J. Knowles Immunoassays for denatured protein analytes, particularly hb alc, and monoclonal antibodies thereto
US4727036A (en) 1985-08-08 1988-02-23 Molecular Diagnostics, Inc. Antibodies for use in determining hemoglobin A1c
DE3806198A1 (de) * 1988-02-04 1989-08-17 Boehringer Mannheim Gmbh Immunogen und seine verwendung zur gewinnung von antikoerpern gegen hba(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)c(pfeil abwaerts)
US5045480A (en) * 1989-02-09 1991-09-03 Miles Inc. Gel particles having hapten moieties bound thereto as immunoassay reagent
US5484735A (en) 1989-08-23 1996-01-16 Northwestern University Immunoassay of glycosylated proteins employing antibody directed to reductively glycosylated N-terminal amino acids
US5164504A (en) * 1991-01-16 1992-11-17 Abbott Laboratories Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives
AU661207B2 (en) * 1992-11-17 1995-07-13 Boehringer Mannheim Gmbh Simultaneous determination of HbA1c and haemoglobin variants with a glycation analogus to HbA1c
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CA2175862A1 (en) * 1995-05-19 1996-11-20 Roberto Sundoro Wu Propoxyphene derivatives for immunoassay reagents
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5955582A (en) 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay

Also Published As

Publication number Publication date
US20030086939A1 (en) 2003-05-08
AU9496998A (en) 1999-04-05
AU749305B2 (en) 2002-06-20
WO1999013907A2 (en) 1999-03-25
WO1999013907A9 (en) 1999-09-10
US7303750B2 (en) 2007-12-04
US20030113339A1 (en) 2003-06-19
WO1999013907A3 (en) 1999-06-03
US20030095976A1 (en) 2003-05-22
US20030077287A1 (en) 2003-04-24
JP2001516567A (ja) 2001-10-02
US6455047B1 (en) 2002-09-24
EP1015028A2 (en) 2000-07-05
US7335516B2 (en) 2008-02-26
US7147858B2 (en) 2006-12-12

Similar Documents

Publication Publication Date Title
AU749305B2 (en) Methods to improve immunogenicity of antigens and specificity of antibodies
US6610297B1 (en) Peptide immunogens for vaccination against and treatment of allergy
JP2000152783A (ja) 免疫活性ペプチドおよび抗体ならびに抗アレルギ―処置におけるそれらの使用
CZ20013081A3 (cs) Epitopy a mimotopy získané z oblastí C-epsilon-2 nebo C-epsilon-4 IgE, jejich antagonisté a jejich terapeutické pouľití
US20040030106A1 (en) Novel compounds and process
DE3806198A1 (de) Immunogen und seine verwendung zur gewinnung von antikoerpern gegen hba(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)c(pfeil abwaerts)
WO2000050460A1 (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
CN111943881A (zh) 溴虫腈半抗原、人工抗原和抗体及其制备方法和应用
US20020168376A1 (en) Compositions of multimeric profilin for diagnosis and treatment of allergies
Axelsen et al. Identification of the shortest Aβ-peptide generating highly specific antibodies against the C-terminal end of amyloid-β42
AU726344B2 (en) High fluorescence specific immune enhancing factor and methods of use for same
Armentano et al. Induction of covalent binding antibodies
AU4250393A (en) Methods and agents for modulating immune response, and uses thereof
US20050214285A1 (en) Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses
WO1994000487A1 (en) Peptide which produces protective immunity against tetanus
Gupta et al. Newly Exposed Immunochemically Cross‐Reactive Epitopes in Sperm‐Specific LDH After Glucosylation and Gossypol Interaction
Mangili et al. Antibodies to human albumin epitopes in type 1 (insulin-dependent) diabetes mellitus
Fitzsimons Generation of cross-reactive monoclonal anti-streptococcal cell membrane antibodies: the evolution of a murine model for Goodpasture's syndrome

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead